Kairos Pharma, Ltd. (KAPA) Fair Value 2026

KAPA · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.1 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (21/100)

Quick Summary — As of 2026-08-28, Kairos Pharma, Ltd. (KAPA) trades at $0.24. QOC: 5.1/10. Value Trap Risk: 21/100 (SAFE). 0/13 models active.

Key Facts

Ticker
KAPA
Price
$0.24
Quality Score
5.1/10
Value Trap Risk
21/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give KAPA?

0 Intrinsic Value Models vs. Current Price ($0.24)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Kairos Pharma, Ltd. (KAPA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Kairos Pharma, Ltd. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About KAPA?

0 of 13 models are currently active for KAPA. See which stocks rank higher →

How Does KAPA Rank in Biotechnology?

Among 625 Biotechnology stocks, KAPA ranks #288 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, Kairos Pharma, Ltd. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating KAPA should weigh these sector-specific dynamics alongside our model-derived fair values.

Is KAPA a Value Trap?

CirclFi's Value Trap algorithm assigns KAPA a score of 21/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Kairos Pharma, Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Kairos Pharma, Ltd.'s fundamental quality profile registers 5.1/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every KAPA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Kairos Pharma, Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

CELUCelularity Inc.QOC 5.1ORICORIC Pharmaceuticals, Inc.QOC 5.1MCRBSeres Therapeutics, Inc.QOC 5.1IMVTImmunovant, Inc.QOC 5.1GDTCCytoMed Therapeutics LimitedQOC 5.1OLMAOlema Pharmaceuticals, Inc.QOC 5.1ENSCEnsysce Biosciences, Inc.QOC 4.5MAJINextel Medical Corp.QOC 2.9RNXTRenovoRx, Inc.QOC 6.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: CELU · ORIC · MCRB · IMVT · GDTC · OLMA · ENSC · MAJI · RNXT · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to KAPA?

6 companies across all industries closest to KAPA’s Quality of Company score of 5.1/10.

PZGParamount Gold Nevada Corp.QOC 5.1GGNGAMCO Global Gold, Natural Resources & Income TrustQOC 5.1CIMGCIMG Inc.QOC 5.1CIFRCipher Digital Inc.QOC 5.1FUNDSprott Focus Trust, Inc.QOC 5.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: PZG · GGN · CIMG · CIFR · FUND · NVDA

Where Does KAPA Sit in CirclFi's Biotechnology Rankings?

KAPA is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Kairos Pharma, Ltd.’s Valuation?

What is Kairos Pharma, Ltd.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Kairos Pharma, Ltd. (KAPA). The Quality of Company score is 5.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is KAPA overvalued or undervalued right now?

At $0.24, 0 of 0 active models suggest KAPA may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Kairos Pharma, Ltd.'s business model in Biotechnology.

What does a Quality of Company score of 5.1 mean for KAPA?

Kairos Pharma, Ltd.'s QOC of 5.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on KAPA?

CirclFi analyzes KAPA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is KAPA a value trap in 2026?

Kairos Pharma, Ltd.'s Value Trap score is 21/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Kairos Pharma, Ltd. (KAPA) a Quality of Company score of 5.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/KAPA/ · Methodology
Primary sources for this KAPA valuation
  • Financial statements: Kairos Pharma, Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001962011) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for KAPA as of ; valuations recomputed .